APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microbiome Therapeutics

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Selected research

Market Analysis & Forecast

Global Microbiome Therapeutics Market Analysis and Forecast 2026-2032

2 January 2026211 pages

Choose your research edition.

Industry ResearchMicrobiome Therapeutics Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbiome Therapeutics Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Microbiome Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbiome Therapeutics Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbiome Therapeutics Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Read the full market overview

The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.

For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.

North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.

Market competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.

Report Includes

This report presents an overview of global market for Microbiome Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Microbiome Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Microbiome Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Microbiome Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Microbiome Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Microbiome Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Microbiome Therapeutics Segment by Company

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

C3 Jian

Rebiotix

MicroBiome Therapeutics LLC

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Symbiotix Biotherapies

Osel

Metabogen

Microbiome Therapeutics Segment by Type

Upper GIT

Lower GIT

Microbiome Therapeutics Segment by Application

C. difficile Infection (CDI)

Inflammatory Bowel Disease (IBD)

Orphan Drug

Immuno-oncology

Others

Microbiome Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Microbiome Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Microbiome Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Microbiome Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Upper GIT Major Player Table 3. Lower GIT Major Player Table 4. Global Microbiome Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. C. difficile Infection (CDI) Major Player Table 6. Inflammatory Bowel Disease (IBD) Major Player Table 7. Orphan Drug Major Player Table 8. Immuno-oncology Major Player Table 9. Others Major Player Table 10. Microbiome Therapeutics Industry Trends Table 11. Microbiome Therapeutics Industry Drivers Table 12. Microbiome Therapeutics Industry Opportunities and Challenges Table 13. Microbiome Therapeutics Industry Restraints Table 14. Global Microbiome Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Microbiome Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Microbiome Therapeutics Market Share by Region (2021-2026) Table 17. Global Microbiome Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Microbiome Therapeutics Market Share by Region (2027-2032) Table 19. Global Microbiome Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Microbiome Therapeutics Revenue Market Share by Players (2021-2026) Table 21. Global Microbiome Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Microbiome Therapeutics Key Players Headquarters & Area Served Table 23. Global Microbiome Therapeutics Players, Product Type & Application Table 24. Global Microbiome Therapeutics Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Microbiome Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Microbiome Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Microbiome Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Microbiome Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Microbiome Therapeutics Revenue Market Share by Type (2021-2026) Table 31. Global Microbiome Therapeutics Revenue Market Share by Type (2027-2032) Table 32. Global Microbiome Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Microbiome Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Microbiome Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Microbiome Therapeutics Revenue Market Share by Application (2021-2026) Table 36. Global Microbiome Therapeutics Revenue Market Share by Application (2027-2032) Table 37. Seres Therapeutics Company Information Table 38. Seres Therapeutics Business Overview Table 39. Seres Therapeutics Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Seres Therapeutics Microbiome Therapeutics Product Portfolio Table 41. Seres Therapeutics Recent Development Table 42. Assembly Biosciences Company Information Table 43. Assembly Biosciences Business Overview Table 44. Assembly Biosciences Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Assembly Biosciences Microbiome Therapeutics Product Portfolio Table 46. Assembly Biosciences Recent Development Table 47. Synthetic Biologics Company Information Table 48. Synthetic Biologics Business Overview Table 49. Synthetic Biologics Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Synthetic Biologics Microbiome Therapeutics Product Portfolio Table 51. Synthetic Biologics Recent Development Table 52. Interxon Company Information Table 53. Interxon Business Overview Table 54. Interxon Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Interxon Microbiome Therapeutics Product Portfolio Table 56. Interxon Recent Development Table 57. PureTech Company Information Table 58. PureTech Business Overview Table 59. PureTech Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. PureTech Microbiome Therapeutics Product Portfolio Table 61. PureTech Recent Development Table 62. Synlogic Company Information Table 63. Synlogic Business Overview Table 64. Synlogic Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Synlogic Microbiome Therapeutics Product Portfolio Table 66. Synlogic Recent Development Table 67. Enterome BioScience Company Information Table 68. Enterome BioScience Business Overview Table 69. Enterome BioScience Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Enterome BioScience Microbiome Therapeutics Product Portfolio Table 71. Enterome BioScience Recent Development Table 72. 4D Pharma Company Information Table 73. 4D Pharma Business Overview Table 74. 4D Pharma Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. 4D Pharma Microbiome Therapeutics Product Portfolio Table 76. 4D Pharma Recent Development Table 77. Second Genome Company Information Table 78. Second Genome Business Overview Table 79. Second Genome Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Second Genome Microbiome Therapeutics Product Portfolio Table 81. Second Genome Recent Development Table 82. AOBiome Company Information Table 83. AOBiome Business Overview Table 84. AOBiome Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. AOBiome Microbiome Therapeutics Product Portfolio Table 86. AOBiome Recent Development Table 87. C3 Jian Company Information Table 88. C3 Jian Business Overview Table 89. C3 Jian Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 90. C3 Jian Microbiome Therapeutics Product Portfolio Table 91. C3 Jian Recent Development Table 92. Rebiotix Company Information Table 93. Rebiotix Business Overview Table 94. Rebiotix Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Rebiotix Microbiome Therapeutics Product Portfolio Table 96. Rebiotix Recent Development Table 97. MicroBiome Therapeutics LLC Company Information Table 98. MicroBiome Therapeutics LLC Business Overview Table 99. MicroBiome Therapeutics LLC Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio Table 101. MicroBiome Therapeutics LLC Recent Development Table 102. Metabiomics Company Information Table 103. Metabiomics Business Overview Table 104. Metabiomics Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 105. Metabiomics Microbiome Therapeutics Product Portfolio Table 106. Metabiomics Recent Development Table 107. Ritter Pharmaceuticals Company Information Table 108. Ritter Pharmaceuticals Business Overview Table 109. Ritter Pharmaceuticals Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 110. Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio Table 111. Ritter Pharmaceuticals Recent Development Table 112. Symberix Company Information Table 113. Symberix Business Overview Table 114. Symberix Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 115. Symberix Microbiome Therapeutics Product Portfolio Table 116. Symberix Recent Development Table 117. OpenBiome Company Information Table 118. OpenBiome Business Overview Table 119. OpenBiome Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 120. OpenBiome Microbiome Therapeutics Product Portfolio Table 121. OpenBiome Recent Development Table 122. Azitra Company Information Table 123. Azitra Business Overview Table 124. Azitra Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 125. Azitra Microbiome Therapeutics Product Portfolio Table 126. Azitra Recent Development Table 127. Symbiotix Biotherapies Company Information Table 128. Symbiotix Biotherapies Business Overview Table 129. Symbiotix Biotherapies Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 130. Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio Table 131. Symbiotix Biotherapies Recent Development Table 132. Osel Company Information Table 133. Osel Business Overview Table 134. Osel Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 135. Osel Microbiome Therapeutics Product Portfolio Table 136. Osel Recent Development Table 137. Metabogen Company Information Table 138. Metabogen Business Overview Table 139. Metabogen Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 140. Metabogen Microbiome Therapeutics Product Portfolio Table 141. Metabogen Recent Development Table 142. North America Microbiome Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 143. North America Microbiome Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 144. North America Microbiome Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 145. North America Microbiome Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 146. North America Microbiome Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. North America Microbiome Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 148. North America Microbiome Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 149. Europe Microbiome Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 150. Europe Microbiome Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 151. Europe Microbiome Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 152. Europe Microbiome Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 153. Europe Microbiome Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. Europe Microbiome Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 155. Europe Microbiome Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 156. China Microbiome Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 157. China Microbiome Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 158. China Microbiome Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 159. China Microbiome Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 160. Asia Microbiome Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 161. Asia Microbiome Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 162. Asia Microbiome Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 163. Asia Microbiome Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 164. Asia Microbiome Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 165. Asia Microbiome Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 166. Asia Microbiome Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 167. SAMEA Microbiome Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 168. SAMEA Microbiome Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 169. SAMEA Microbiome Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 170. SAMEA Microbiome Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 171. SAMEA Microbiome Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 172. SAMEA Microbiome Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 173. SAMEA Microbiome Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 174. Research Programs/Design for This Report Table 175. Authors List of This Report Table 176. Secondary Sources Table 177. Primary Sources List of Figures Figure 1. Microbiome Therapeutics Image Figure 2. Global Microbiome Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Microbiome Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Upper GIT Image Figure 5. Lower GIT Image Figure 6. Global Microbiome Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Microbiome Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. C. difficile Infection (CDI) Image Figure 9. Inflammatory Bowel Disease (IBD) Image Figure 10. Orphan Drug Image Figure 11. Immuno-oncology Image Figure 12. Others Image Figure 13. Global Microbiome Therapeutics Market Size (US$ Million) & (2021-2032) Figure 14. Global Microbiome Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Microbiome Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Microbiome Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Microbiome Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Microbiome Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Microbiome Therapeutics Revenue Market Share by Type (2021-2032) Figure 21. Global Microbiome Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Microbiome Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Microbiome Therapeutics Revenue Market Share by Application (2021-2032) Figure 24. North America Microbiome Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Microbiome Therapeutics Revenue Share by Type (2021-2032) Figure 26. North America Microbiome Therapeutics Revenue Share by Application (2021-2032) Figure 27. North America Microbiome Therapeutics Revenue Share by Country (2021-2032) Figure 28. United States Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Microbiome Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Microbiome Therapeutics Revenue Share by Type (2021-2032) Figure 33. Europe Microbiome Therapeutics Revenue Share by Application (2021-2032) Figure 34. Europe Microbiome Therapeutics Revenue Share by Country (2021-2032) Figure 35. Germany Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Microbiome Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Microbiome Therapeutics Revenue Share by Type (2021-2032) Figure 45. China Microbiome Therapeutics Revenue Share by Application (2021-2032) Figure 46. Asia Microbiome Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Microbiome Therapeutics Revenue Share by Type (2021-2032) Figure 48. Asia Microbiome Therapeutics Revenue Share by Application (2021-2032) Figure 49. Asia Microbiome Therapeutics Revenue Share by Region (2021-2032) Figure 50. Japan Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Microbiome Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Microbiome Therapeutics Revenue Share by Type (2021-2032) Figure 58. SAMEA Microbiome Therapeutics Revenue Share by Application (2021-2032) Figure 59. SAMEA Microbiome Therapeutics Revenue Share by Country (2021-2032) Figure 60. Brazil Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Upper GIT
  • Lower GIT
Applications
  • C. difficile Infection (CDI)
  • Inflammatory Bowel Disease (IBD)
  • Orphan Drug
  • Immuno-oncology
  • Others
Companies covered
  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Interxon
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • AOBiome
  • C3 Jian
  • Rebiotix
  • MicroBiome Therapeutics LLC
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Symbiotix Biotherapies
  • Osel
  • Metabogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Microbiome Therapeutics Market by Type
  3. 1.2.1 Global Microbiome Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Upper GIT
  5. 1.2.3 Lower GIT
  6. 1.3 Microbiome Therapeutics Market by Application
  7. 1.3.1 Global Microbiome Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 C. difficile Infection (CDI)
  9. 1.3.3 Inflammatory Bowel Disease (IBD)
  10. 1.3.4 Orphan Drug
  11. 1.3.5 Immuno-oncology
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Microbiome Therapeutics Market Dynamics
  1. 2.1 Microbiome Therapeutics Industry Trends
  2. 2.2 Microbiome Therapeutics Industry Drivers
  3. 2.3 Microbiome Therapeutics Industry Opportunities and Challenges
  4. 2.4 Microbiome Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Microbiome Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Microbiome Therapeutics Growth Trends by Region
  3. 3.2.1 Global Microbiome Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Microbiome Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Microbiome Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Microbiome Therapeutics Revenue by Players
  2. 4.1.1 Global Microbiome Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Microbiome Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Microbiome Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Microbiome Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Microbiome Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Microbiome Therapeutics Players, Product Type & Application
  8. 4.5 Global Microbiome Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Microbiome Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Microbiome Therapeutics Tier 1, Tier 2, and Tier 3
5 Microbiome Therapeutics Market Size by Type
  1. 5.1 Global Microbiome Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Microbiome Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Microbiome Therapeutics Revenue Market Share by Type (2021-2032)
6 Microbiome Therapeutics Market Size by Application
  1. 6.1 Global Microbiome Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Microbiome Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Microbiome Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Seres Therapeutics
  2. 7.1.1 Seres Therapeutics Company Information
  3. 7.1.2 Seres Therapeutics Business Overview
  4. 7.1.3 Seres Therapeutics Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
  6. 7.1.5 Seres Therapeutics Recent Developments
  7. 7.2 Assembly Biosciences
  8. 7.2.1 Assembly Biosciences Company Information
  9. 7.2.2 Assembly Biosciences Business Overview
  10. 7.2.3 Assembly Biosciences Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
  12. 7.2.5 Assembly Biosciences Recent Developments
  13. 7.3 Synthetic Biologics
  14. 7.3.1 Synthetic Biologics Company Information
  15. 7.3.2 Synthetic Biologics Business Overview
  16. 7.3.3 Synthetic Biologics Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
  18. 7.3.5 Synthetic Biologics Recent Developments
  19. 7.4 Interxon
  20. 7.4.1 Interxon Company Information
  21. 7.4.2 Interxon Business Overview
  22. 7.4.3 Interxon Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Interxon Microbiome Therapeutics Product Portfolio
  24. 7.4.5 Interxon Recent Developments
  25. 7.5 PureTech
  26. 7.5.1 PureTech Company Information
  27. 7.5.2 PureTech Business Overview
  28. 7.5.3 PureTech Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 PureTech Microbiome Therapeutics Product Portfolio
  30. 7.5.5 PureTech Recent Developments
  31. 7.6 Synlogic
  32. 7.6.1 Synlogic Company Information
  33. 7.6.2 Synlogic Business Overview
  34. 7.6.3 Synlogic Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Synlogic Microbiome Therapeutics Product Portfolio
  36. 7.6.5 Synlogic Recent Developments
  37. 7.7 Enterome BioScience
  38. 7.7.1 Enterome BioScience Company Information
  39. 7.7.2 Enterome BioScience Business Overview
  40. 7.7.3 Enterome BioScience Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
  42. 7.7.5 Enterome BioScience Recent Developments
  43. 7.8 4D Pharma
  44. 7.8.1 4D Pharma Company Information
  45. 7.8.2 4D Pharma Business Overview
  46. 7.8.3 4D Pharma Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
  48. 7.8.5 4D Pharma Recent Developments
  49. 7.9 Second Genome
  50. 7.9.1 Second Genome Company Information
  51. 7.9.2 Second Genome Business Overview
  52. 7.9.3 Second Genome Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Second Genome Microbiome Therapeutics Product Portfolio
  54. 7.9.5 Second Genome Recent Developments
  55. 7.10 AOBiome
  56. 7.10.1 AOBiome Company Information
  57. 7.10.2 AOBiome Business Overview
  58. 7.10.3 AOBiome Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AOBiome Microbiome Therapeutics Product Portfolio
  60. 7.10.5 AOBiome Recent Developments
  61. 7.11 C3 Jian
  62. 7.11.1 C3 Jian Company Information
  63. 7.11.2 C3 Jian Business Overview
  64. 7.11.3 C3 Jian Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  65. 7.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
  66. 7.11.5 C3 Jian Recent Developments
  67. 7.12 Rebiotix
  68. 7.12.1 Rebiotix Company Information
  69. 7.12.2 Rebiotix Business Overview
  70. 7.12.3 Rebiotix Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
  72. 7.12.5 Rebiotix Recent Developments
  73. 7.13 MicroBiome Therapeutics LLC
  74. 7.13.1 MicroBiome Therapeutics LLC Company Information
  75. 7.13.2 MicroBiome Therapeutics LLC Business Overview
  76. 7.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  77. 7.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
  78. 7.13.5 MicroBiome Therapeutics LLC Recent Developments
  79. 7.14 Metabiomics
  80. 7.14.1 Metabiomics Company Information
  81. 7.14.2 Metabiomics Business Overview
  82. 7.14.3 Metabiomics Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
  84. 7.14.5 Metabiomics Recent Developments
  85. 7.15 Ritter Pharmaceuticals
  86. 7.15.1 Ritter Pharmaceuticals Company Information
  87. 7.15.2 Ritter Pharmaceuticals Business Overview
  88. 7.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
  90. 7.15.5 Ritter Pharmaceuticals Recent Developments
  91. 7.16 Symberix
  92. 7.16.1 Symberix Company Information
  93. 7.16.2 Symberix Business Overview
  94. 7.16.3 Symberix Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Symberix Microbiome Therapeutics Product Portfolio
  96. 7.16.5 Symberix Recent Developments
  97. 7.17 OpenBiome
  98. 7.17.1 OpenBiome Company Information
  99. 7.17.2 OpenBiome Business Overview
  100. 7.17.3 OpenBiome Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  101. 7.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
  102. 7.17.5 OpenBiome Recent Developments
  103. 7.18 Azitra
  104. 7.18.1 Azitra Company Information
  105. 7.18.2 Azitra Business Overview
  106. 7.18.3 Azitra Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Azitra Microbiome Therapeutics Product Portfolio
  108. 7.18.5 Azitra Recent Developments
  109. 7.19 Symbiotix Biotherapies
  110. 7.19.1 Symbiotix Biotherapies Company Information
  111. 7.19.2 Symbiotix Biotherapies Business Overview
  112. 7.19.3 Symbiotix Biotherapies Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
  114. 7.19.5 Symbiotix Biotherapies Recent Developments
  115. 7.20 Osel
  116. 7.20.1 Osel Company Information
  117. 7.20.2 Osel Business Overview
  118. 7.20.3 Osel Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Osel Microbiome Therapeutics Product Portfolio
  120. 7.20.5 Osel Recent Developments
  121. 7.21 Metabogen
  122. 7.21.1 Metabogen Company Information
  123. 7.21.2 Metabogen Business Overview
  124. 7.21.3 Metabogen Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Metabogen Microbiome Therapeutics Product Portfolio
  126. 7.21.5 Metabogen Recent Developments
8 North America
  1. 8.1 North America Microbiome Therapeutics Revenue (2021-2032)
  2. 8.2 North America Microbiome Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Microbiome Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Microbiome Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Microbiome Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Microbiome Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Microbiome Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Microbiome Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Microbiome Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Microbiome Therapeutics Revenue by Country
  11. 8.6.1 North America Microbiome Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Microbiome Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Microbiome Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Microbiome Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Microbiome Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Microbiome Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Microbiome Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Microbiome Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Microbiome Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Microbiome Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Microbiome Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Microbiome Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Microbiome Therapeutics Revenue by Country
  11. 9.6.1 Europe Microbiome Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Microbiome Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Microbiome Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Microbiome Therapeutics Revenue (2021-2032)
  2. 10.2 China Microbiome Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Microbiome Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Microbiome Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Microbiome Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Microbiome Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Microbiome Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Microbiome Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Microbiome Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Microbiome Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Microbiome Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Microbiome Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Microbiome Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Microbiome Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Microbiome Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Microbiome Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Microbiome Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Microbiome Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Microbiome Therapeutics Revenue by Country
  11. 11.6.1 Asia Microbiome Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Microbiome Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Microbiome Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Microbiome Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Microbiome Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Microbiome Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Microbiome Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Microbiome Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Microbiome Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Microbiome Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Microbiome Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Microbiome Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Microbiome Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Microbiome Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Microbiome Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Microbiome Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst